Welcome to our dedicated page for Edgewise Therapeutics SEC filings (Ticker: EWTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Edgewise Therapeutics, Inc. filings document a late-stage clinical biopharmaceutical company developing treatments for severe muscle diseases, including programs for muscular dystrophies and serious cardiac conditions. Form 8-K reports furnish quarterly and annual financial results, Regulation FD clinical-program disclosures, and material governance events.
The company’s proxy materials describe board structure, director elections, executive compensation, equity-award information, stockholder voting matters, and governance practices. Other disclosed matters include officer appointments, director appointments, compensatory arrangements, exhibits to earnings releases, and operating context for a development-stage drug pipeline.
Edgewise Therapeutics insider Russell Alan J reported multiple equity transactions on 08/12/2025. He acquired 5,781 shares via vesting of RSUs and sold 1,907 shares in a sell-to-cover to satisfy tax withholding at an average sale price of $13.3924 per share (individual sale prices ranged $13.36–$13.49). After these transactions he beneficially owns 23,400 shares.
The filing also shows newly granted compensation awards: 5,781 RSUs vesting in four equal annual installments beginning 08/12/2025, 28,125 RSUs vesting in four equal annual installments beginning 08/12/2026, and a stock option to purchase 168,750 shares at an exercise price of $13.39 per share exercisable beginning 09/12/2025 with a 08/12/2035 expiration. The report identifies Russell as Chief Scientific Officer and a director.
Edgewise Therapeutics insider transactions: Kevin Koch, President and CEO and director, reported multiple equity awards and a sell-to-cover on 08/12/2025. He received 17,968 RSUs that vested (or were deemed acquired) and an additional 87,500 RSUs granted with staggered vesting beginning 08/12/2026. He was also granted a 525,000-share stock option exercisable at $13.39 per share with monthly vesting starting 09/12/2025. To satisfy tax withholding, 7,972 shares were sold at an average price of $13.3924. Following these transactions, he beneficially owned 30,615 shares directly and 259,554 shares indirectly through family entities.
Insider transactions by CMO Joanne M. Donovan at Edgewise Therapeutics (EWTX): On 08/12/2025 Donovan was issued 168,750 stock options exercisable at $13.39 and 28,125 RSUs (vesting beginning 08/12/2026) and received 5,781 RSUs (vesting beginning 08/12/2034). She also acquired 5,781 shares and sold 2,862 shares in a sell-to-cover to satisfy tax withholding at an average price of $13.3924. Following these transactions she beneficially owned 25,361 common shares.
Edgewise Therapeutics, Inc. received an Amendment No. 1 to a Schedule 13G filed by Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker reporting aggregate beneficial ownership of 7,305,940 shares of common stock, representing 6.9% of the 105,200,221 shares outstanding used for the calculation. The filing states the Adviser has sole investment and voting power over those shares through management agreements with two funds, Baker Brothers Life Sciences, L.P. and 667, L.P., which directly hold 6,762,577 and 543,363 shares respectively. The disclosure is presented as an amendment and certifies the securities are held in the ordinary course of business and not to change or influence control of the issuer.
Janus Henderson Group plc filed a Schedule 13G/A reporting beneficial ownership of Edgewise Therapeutics common stock. The filing lists an aggregate holding of 5,503,349 shares, representing 5.2% of the class, with shared voting and shared dispositive power. The filing also states that certain indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) are registered investment advisers to managed portfolios, and Item 4 separately indicates JHIUS may be deemed to beneficially own 5,437,423 shares (also shown as 5.2%). The statement includes a certification that the shares are held in the ordinary course of business and not to influence control. The filing is signed by Kristin Mariani on 08/14/2025.
Edgewise Therapeutics (Nasdaq:EWTX) filed an 8-K furnishing upbeat interim data on sevasemten for Becker and Duchenne muscular dystrophies and summarizing recent FDA guidance.
- MESA extension (n = 85): 0.8-point NSAA improvement over 18 months, 3-year disease stabilization and 99 % rollover from prior studies.
- Placebo switchers gained 0.2 NSAA points.
- Safety remains favorable after up to three years.
- FDA confirmed NSAA as a meaningful endpoint and indicated the ongoing GRAND CANYON study (topline Q4 2026) could be a single pivotal trial for Becker registration.
- Duchenne Phase 2 LYNX & FOX: Well-tolerated across doses; 10 mg selected for Phase 3 after functional and biomarker benefits.
Management plans a Phase 3 design meeting with FDA in Q4 2025 and expects pivotal Duchenne enrollment in 2026. No financial metrics were disclosed.
Form 4 Filing Details: Laura Brege, Director of Edgewise Therapeutics (EWTX), received a stock option grant on June 16, 2025. The transaction involves the following key details:
- Granted 30,000 stock options to purchase common stock
- Exercise price set at $14.68 per share
- Options will vest fully on the earlier of: - June 16, 2026 - Day before 2026 annual stockholder meeting
- Options expire on June 16, 2035
This grant represents standard director compensation and aligns the director's interests with shareholders through long-term equity incentives. The filing was submitted by John R. Moore as attorney-in-fact for Laura Brege on June 18, 2025.